Centre of Perinatal and Reproductive Medicine, Department of Gynecological, Obstetrical, and Pediatric Sciences, University of Perugia, Italy.
Patient(s)
Three hundred seventy-six postmenopausal healthy women, all with intact uterus.
Intervention(s)
Women were distributed in two different groups using randomized criteria: group A (n = 179) patients received soy tablets (150 mg of isoflavones per day) for 5 years; group B (n = 197) patients received identical appearing placebo tablets for 5 years.
Main outcome measure(s)
Results of endometrial histology from biopsies obtained at baseline, 30 months, and 5 years after the beginning of the treatment.
Result(s)
Two hundred ninety-eight women completed the 5-year treatment. No cases of malignancy were detected during biopsy. Seventy percent of women undergoing treatment with soy phytoestrogens had an endometrium classified as atrophic or nonassessable versus 81% receiving placebo. The occurrence of endometrial hyperplasia was significantly higher in group A (3.37% vs. 0%).
Conclusion(s)
Long-term treatment (up to 5 years) with soy phytoestrogens was associated with an increased occurrence of endometrial hyperplasia. These findings call into question the long-term safety of phytoestrogens with regard to the endometrium.
aA.G.UN.CO., Obstetrics and Gynecology Centre, Rome, Italy
bDepartment of Human Physiology and Pharmacology “Vittorio Erspamer,” University “La Sapienza,” Rome, Italy
cCentre of Perinatal and Reproductive Medicine, Department of Gynecological, Obstetrical, and Pediatric Sciences, University of Perugia, Perugia, Italy
Reprint requests: Prof. Vittorio Unfer, A.G.UN.CO. Obstetrics and Gynecology Centre, Via G. Cassiani, 15-00155 Rome, Italy (FAX: 39-06-3241284).